tbuckley/cabot-search huggingface dataset:
674P Real-world outcomes of first-line platinum doublet chemotherapy plus Tyrosine Kinase Inhibitors (TKI) in advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
Authors: Y.F. Low, G. Lai, A. Seet, W.C. Tan, A.C. Tan, J. Chan, Y.L. Teh, W.L. Tan, A. Jain, Q.S. Ng, M-K. Ang, R. Kanesvaran, D.W-T. Lim, D.S.W. Tan, P.L.S. Saw
Journal: Annals of Oncology (2024)
617P Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
Authors: H. Kikuchi, H. Mizugaki, K. Tsuji, K. Yokoo, K. Tsurumi, J. Sugisaka, N. Kimura, H. Yokouchi, T. Sumi, Y. Kawai, K. Kobashi, R. Morita, K. Ito, Y. Kitamura, H. Minemura, K. Nakamura, H. Tanaka, T. Takashina, S. Konno, S. Oizumi
Journal: Annals of Oncology (2024)
648P The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study
Authors: S. Kataoka, T. Shukuya, D. Fujimoto, H. Ohtsu, T. Miyawaki, Y. Toi, T. Yokoyama, T. Kato, T. Yamaguchi, S. Miura, M. Tamiya, M. Tachihara, K. Otsubo, Y. Sato, S. Ikeda, N. Yamamoto, K. Takahashi, H. Hayashi, I. Okamoto
Journal: Annals of Oncology (2024)
762P Systemic treatment for patients with advanced Merkel cell carcinoma in Japan: A multicenter retrospective study
Authors: E. Nakano, M. Nakamura, S. Kawashima, A. Maruyama, S. Ohe, J. Kato, T. Fujimura, W. Omata, T. Funakoshi, Y. Fujisawa, T. Maekawa, K. Yamakawa, N. Hatta, K. Nakama, T. Ito, S. Matsushita, T. Miyagawa, K. Oashi, Y. Yamamoto, K. Namikawa
Journal: Annals of Oncology (2024)
636P SKYSCRAPER-02C: Phase III study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) in China
Authors: S. Lu, J. Fang, Y. Yu, Y. Fan, X. Dong, H. Wang, C. Lin, L. Zhang, R.D. Meng
Journal: Annals of Oncology (2024)
654P Efficacy and safety of first-line ipilimumab and nivolumab treatment in elderly patients with non-small cell lung cancer
Authors: H. Imai, A. Mouri, S. Endo, K. Tsukamoto, K. Masaki, K. Hashimoto, Y. Miura, A. Shiono, O. Yamaguchi, J. Nakagawa, K. Kaira, K. Kobayashi, H. Kagamu
Journal: Annals of Oncology (2024)
646P Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study
Authors: W.F. Fang, Y. Yang, Y. Zhao, Y. Huang, H. Zhao, N. Zhou, Y. Zhang, L. Chen, T. Zhou, G. Chen, H. Li, T. Wu, S. Xue, X. Kang, L. Zhang
Journal: Annals of Oncology (2024)
676P NEJ053C: A phase II study of nivolumab and ipilimumab combined with chemotherapy after lung stereotactic body radiotherapy as first-line therapy for stage IV non-small cell lung cancer
Authors: K. Watanabe, K. Ito, T. Sumi, O. Fujii, H. Imai, K. Kaira, K. Nemoto Murofushi, S. Kato, S. Morita, H. Kagamu, K. Kobayashi, Y. Hosomi
Journal: Annals of Oncology (2024)
733P Real-world experience with a multi-cancer early detection test in Southeast Asia
Authors: D.L.H. Nguyen, L.S. Tran, O. Trachoo, T. Weerasamai, P. Khongthong, K. Tienchai, F.V.F. Que, A. Punzalan, P.J. Roselle-Ubial, C. Flores, C. Lola, H. Delizo, H. Noviana, W. Yang, V. Saputra, C.W. Wong, H.T-H. Nguyen, C.V.T. Nguyen, S.H. Tang, S.D. Nguyen
Journal: Annals of Oncology (2024)
681P Characterising the genomic landscape of advanced non-squamous NSCLC of Chinese: A territory-wide study in Hong Kong
Authors: A. El-Helali, E.Y-L. Ko, C.H.L. Wong, K.M. Cheung, M.K.L. Chiu, S.F. Nyaw, T.Y. Kam, M.Y. Lim, S.T.F. Mok, C.K. Kwan, D. Leung, K.K. Yuen, A.W.M. Lee, V.H.F. Lee
Journal: Annals of Oncology (2024)
713P Multicenter observational study on combination immunotherapy for extensive-stage small cell lung cancer
Authors: Y. Masui, T. Mimori, M. Motojima, K. Shibayama, T. Miyawaki, Y. Namba, T. Shukuya, R. Koyama, N. Shimada, K. Kenji, S. Sasaki, K. Takahashi
Journal: Annals of Oncology (2024)
663P Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR) vs. Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ): Propensity score matching (PSM) real-world data (RWD) on CDDP-fit extensive disease (ED)-small cell lung cancer (SCLC)
Authors: K. Hamai, K. Hirano, A. Hata, Y. Yamanaka, T. Sumi, Y. Sato, Y. Oya, N. Katakami, K. Iwasaki, T. Uenishi, K. Kokubo
Journal: Annals of Oncology (2024)
746P Impact of adjuvant (AC)and neoadjuvant (NAC) chemotherapy in patients (pts) with soft tissue sarcoma (STS): A real-life exhaustive nationwide study (DEEPSARC)
Authors: J-Y. Blay, V. Thevenet, E. Oger, F. Gouin, A. Happe, E. Drezen, A. Le Cesne, M. Toulmonde, S. Bonvalot, F. Le Loarer, M. Karanian, C. Ngo, G. De Pinieux, A. Gomez-Mascard, F. Ducimetiere, C. Chemin-Airiau, H. Crochet, N. Huchet, N. Penel, S. Mathoulin
Journal: Annals of Oncology (2024)
698P First-line aumolertinib in EGFR-mutant pulmonary adenosquamous carcinoma: Updated overall survival of the multicenter, single-arm, prospective study (ARISE)
Authors: L.F. Zhang, L. Huang, D. Huang, Z. Liu, Y. Yu, K. Miao, Q. Miao, X. Zheng, Y. Xu, Q. Chu, G. Lin
Journal: Annals of Oncology (2024)
694P Chemoimmunotherapy versus pembrolizumab as a first-line treatment for patients with advanced non-small cell lung cancer and high PD-L1 expression: Focus on the role of performance status
Authors: T. Yamada, K. Morimoto, H. Kawachi, M. Tamiya, Y. Negi, Y. Goto, A. Nakao, S. Shiotsu, K. Tanimura, A. Okada, T. Harada, K. Date, Y. Chihara, I. Hasegawa, N. Tamiya, T. Kijima, K. Takayama
Journal: Annals of Oncology (2024)
639P A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)
Authors: M. Tachihara, H. Shoda, Y. Akazawa, T. Ota, M. Oki, Y. Sato, S. Sugawara, S. Ikeda, T. Yokoyama, H. Kaneda, S. Itoh, A. Bessho, N. Katakami, S. Morita, K. Nakagawa, I. Okamoto, N. Yamamoto
Journal: Annals of Oncology (2024)
769P The prognostic impact of CDKN2A/B heterozygous deletions in meningioma-insights of a multicenter analysis
Authors: F.M. Ippen, T. Hielscher, A. Patel, D. Friedel, K. Göbel, S. Maas, A. von Deimling, W. Wick, A. Suwala, F. Sahm
Journal: Annals of Oncology (2024)
693P Treatment comparison of amivantamab vs. real-world therapies among patients with NSCLC harboring EGFR Exon 20 insertion mutations: An external control analysis (ECA) using NTUH NSCLC dataset in Taiwan
Authors: J-Y. Wu, J. Zhuo, E. Chen, S-P. Wang, J-F. Hsieh, J-Y. Shih
Journal: Annals of Oncology (2024)
660P Proteogenomic analysis of CSF reveals molecular patterns and potential drug targets of leptomeningeal metastases in EGFR+ NSCLC
Authors: M. Zheng, L-B. Tang, S-H. Lin, Y-S. Li, K. Yin, G. Wang, C-C. Li, X-R. Sun, P. Li, X. Zhang, S-X. Gao, Q. Zhou, H. Tu, H-J. Chen, P. Yi, W-Z. Zhong, C.C. Wong, Y-L. Wu
Journal: Annals of Oncology (2024)
742P 18F-FDG PET/CT can stratify the prognosis of standard responders after neoadjuvant chemotherapy in osteosarcoma
Authors: T. Takemori, E. Kobayashi, H. Kondo, S. Osaki, K. Ogura, S. Iwata, A. Kawai, K. Ito
Journal: Annals of Oncology (2024)
594P Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II–IIIB NSCLC: CheckMate 77T Chinese population analysis
Authors: J. He, L. Wu, Y. Gao, K. Ying, G. Jiang, K-Y. Lee, C. Chen, H. Zhong, S. Liu, F. Xiong, K-N. Chen, L. Liu, L. Tan, W. Wang, J-Y. Shih, H. Sun, W. Kang, H. Zhang, S. Lu
Journal: Annals of Oncology (2024)
649P An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome
Authors: B. Han, B. Yan, T. Chu, H. Zhong, W. Zhang, C. Shi, H. Wang, X. Zhang, A. Gu
Journal: Annals of Oncology (2024)
678P Ramucirumab plus Erlotinib (RAM+ERL) for advanced non-small cell lung cancer (NSCLC) harboring EGFR L858R mutation (L858R mut): A multicenter retrospective observational cohort study (REAL-SPEED)
Authors: M. Ishihara, T. Kawamura, Y. Nanba, Y. Takeyasu, Y. Hasegawa, Y. Sato, Y. Negi, T. Oba, T. Sumi, H. Hirata, H. Funabashi, Y. Oya, H. Kikuchi, N. Katsurada, T. Nakatani, T. Harada, T. Misumi, N. Matsutani, N. Seki
Journal: Annals of Oncology (2024)
662P Comparison of atezolizumab/etoposide/platinum and durvalumab/etoposide/platinum for extensive-stage small cell lung cancer in Japan: A multicenter retrospective observational study
Authors: H. Sakashita, T. Aiba, S. Hara, T. Kamoshida, R. Yamamoto, T. Sakaguchi, J. Koshio, Y. Ando, A. Takigami, M. Maemondo, S. Sugawara
Journal: Annals of Oncology (2024)
600P Real-world treatment patterns and survival in resectable stage I-III NSCLC: THASSOS INTL Middle East and Africa (MEA) cohort
Authors: A.H. Abdelaziz, M.S. Emam, M.A.M.A.H. Alnassar, E. Dawoud, A. Seyam, M. Mancy, V. Rajadhyaksha, A. Isikdogan, A. Sezer
Journal: Annals of Oncology (2024)
629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC)
Authors: C. Zhou, Y. Lu, S-W. Kim, T.R. Baisamut, J. Zhou, Y. Zhang, J. He, J-J. Yang, Y. Cheng, S-H. Lee, J. Chang, J. Fang, Z. Liu, L. Bu, L. Qian, V.R. Archer, M. Zhou, L. Zhang
Journal: Annals of Oncology (2024)
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis
Authors: S.W. Tse, M. Day, O. Kuszaj, S. Caini, D. Vesprini, S. Bosnic, W. Chan, S.F. Lee, I. Karam, G. Marta, F. Gallant, E. Chow, H. Wong
Journal: Annals of Oncology (2024)
631P Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial
Authors: H. Kim, S. Park, T.M. Kim, J-Y. Han, G-W. Lee, B.Y. Shim, Y-G. Lee, S-W. Kim, C-Y. Ock, S. Hwang, Y. Lee, R. Kim, H.A. Jung, J-M. Sun, S-H. Lee, J.S. Ahn, M-J. Ahn
Journal: Annals of Oncology (2024)
641P METRIX: International real-world study of c-Met protein overexpression in patients with non-small cell lung cancer
Authors: H. Horinouchi, Z. Xu, S. Savic Prince, P. De la Iglesia, D.H. Enrico, P. Desmeules, A. Koslucher, P.J. Ansell, R. Thiébaut, C. Hader
Journal: Annals of Oncology (2024)
731P Development and Implementation of an organized community-approach clinical screening program for cervical, breast and oral cancers in Nawly, Jashore in Bangladesh
Authors: E.Y.T. Wong, S.A. Hamid, M.R. Azim, M.H. Takukder, M.S. Islam, M.M. Rahman, T. Joarder, R. Kanesvaran
Journal: Annals of Oncology (2024)
658P Furmonertinib 160mg as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 21 L858R mutation
Authors: M. Shi, B. Shen, C. Wang, L. Zhang, Y. Zhu, L. Wang, Z. Guo
Journal: Annals of Oncology (2024)
703P Efficacy and safety of lurbinectedin in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter, retrospective real-world study
Authors: Y. Xiang, Y. Tang, T. Luan, L. Mengchen, W. Shi, A.G.W. Chin, X. Feng, F. Wang, X.W. Sun, Z. Bao, J. Zhou, J. Zhao, H. Wu, D. Fu
Journal: Annals of Oncology (2024)
736P Loss of interest in academic careers among young oncology residents: A French longitudinal survey
Authors: N. Taranto, M. Duval, C. Raynaud, A. Boileve, N. Naoun, A. Rousseau, E. Ashton, L. Ollivier, J. Alexandre, F. Huguet, M. Kfoury, M. Delaye, M. Hilmi
Journal: Annals of Oncology (2024)
726TiP A multicenter cluster randomized controlled study to evaluate guideline adoption through lung cancer clinical care quality improvement project (QIP) in pulmonary and critical care medicine (PCCM) department in China
Authors: W. li, Y. Ren, C. Hu, Y. Song, S. Yang, C. Zhou, X. Zhang, Y. Zhang, B. Cao, C. Wang
Journal: Annals of Oncology (2024)
764P Neutrophil to lymphocyte ratio (NLR) as a prognostic biomarker in melanoma patients treated with immune checkpoint inhibitors
Authors: O. Oey, W. Wijaya, M.A. Khattak, A. Abed, T. Meniawy, A. Reid, L. Calapre, M. Millward, E.S. Gray
Journal: Annals of Oncology (2024)
638P Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial
Authors: A.C. Tan, T.M. Kim, S. Zhou, L. Yueh Ni, G.F. Ho, L.M. Tho, T. Reungwetwattana, N. Prasongsook, S. Lee, S.H. Tan, D-W. Kim, T.S.K. Mok, D.S.W. Tan, H.H.F. Loong
Journal: Annals of Oncology (2024)
669P A retrospective observational study on the efficacy of local ablative therapy for oligoprogression in non-small cell lung cancer patients who responded to immunotherapy combined chemotherapy
Authors: S. Kuyama, T. Ninomiya, M. Yasugi, K. Kudo, K. Ninomiya, M. Inoue, F. Onishi, H. Ichikawa, I. Oze, Y. Maeda, K. Hotta
Journal: Annals of Oncology (2024)
LBA6 PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
Authors: Y-L. Wu, L. Wu, N. Bi, T. Cil, H. Ge, Z. Zhu, C-L. Wang, W. Zhang, D. Lv, M. E, J. Sun, Y. Pan, M. Krzakowski, M. Dikilitas, M.A.N. Sendur, Y-C. Kim, Y. Yang, R. Mao, B. Zhang, L. Wang
Journal: Annals of Oncology (2024)
611P Cost-effectiveness of perioperative ICI therapy with NSCLC in Japan, USA, Brazil
Authors: T. Aranishi, M. Fujioka, T. Shukuya, L.H. Araujo, D.H. Owen, T. Sowers, Y. Shirai, D.P. Carbone, K. Takahashi
Journal: Annals of Oncology (2024)
723TiP Liposomal irinotecan (Lipo-IRI) alone or in combination with famitinib or platinum for patients with extensive-stage small cell lung cancer (ES-SCLC) after failure of first-line immunotherapy: A multicenter, randomized, open-label, multicohort phase II trial
Authors: H. Xu, H. Shi, W. Jiang, Y. Yang, S-Y. Lei, L. Tian, R. Sun, C. Zhang, S. Nan, Y. Wang
Journal: Annals of Oncology (2024)
619P Pathologic complete response is the essential element for surgical modification after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading lobar bronchial orifice: A multicenter retrospective cohort study
Authors: H. Zhang, T. Ma, J. Yi, Y. Ge, H. Yang, J. Wang, S. Li, R. Ma, G. Zhang, P. Song, H. Peng, F. Yao
Journal: Annals of Oncology (2024)
543P Clinical practice of anamorelin therapy for cachexia in pancreatic cancer
Authors: M. Okada, A. Ohba, S. Mitsunaga, T. Shibuki, T. Satake, K. Watanabe, M. Sasaki, H. Imaoka, Y. Maruki, Y. Nagashio, H. Susumu, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka
Journal: Annals of Oncology (2024)
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC
Authors: H.A. Jung, D. Lee, B. Park, K. Lee, H.Y. Lee, T.J. Kim, Y.J. Jeon, J. Lee, S.Y. Park, J.H. Cho, Y.S. Choi, S. Park, J-M. Sun, S-H. Lee, J.S. Ahn, M-J. Ahn, H.K. Kim
Journal: Annals of Oncology (2024)
LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1
Authors: N. Yamamoto, H. Tu, M-J. Ahn, K. Yoh, J. Zugazagoitia, E.F. Smit, Y-L. Wu, D. Planchard, B.C. Cho, B. Wehler, Y. Zhao, E. Nadal, G. Lin, U. von Wangenheim, M. Rohrbacher, B. Sadrolhefazi, J. Heymach, G. Ruiter
Journal: Annals of Oncology (2024)
677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China
Authors: P. Xing, D. Lv, W. Feng, S. Liu, Y. Yu, J. Yin, X. Ren, J. Zhang, G. Han, Y. Zhang, S. Cang, J. Chen, E. Chen, L. Meng, Y. Zhang, Y-K. Shi
Journal: Annals of Oncology (2024)
593TiP The efficacy and safety of mirtazapine vs olanzapine in preventing chemotherapy induced nausea and vomiting in combination with the triplet regimen in patients receiving highly emetogenic chemotherapy: An open label, prospective, randomized control study
Authors: A. Mruthyunjaya Swamy, A. Sehrawat, D. Sundriyal
Journal: Annals of Oncology (2024)
598P Genomic profiling for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-advantage/MRD
Authors: Y. Zenke, K. Yoh, S. Kitagawa, J. Samejima, T. Kasugai, H. Saijo, Y. Kimura, S. Miyamoto, S. Hara, M. Kawakami, H. Izumi, S. Matsumoto, Y. Tanaka, T. Sakai, H. Udagawa, E. Sugiyama, S. Umemura, M. Tsuboi, K. Goto
Journal: Annals of Oncology (2024)
628MO Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3
Authors: S-H. Lee, H. Akamatsu, J.C-H. Yang, S.M. Lim, B. Liu, T. John, J. Wang, Y. Ohe, M. Kondo, M. Tamiya, P. Danchaivijitr, P-C. Hsu, J. Zhuo, C. Saadoun, N. Saxena, G. Balaburski, L. Ribeiro, M. Gamil, M. Baig, Y. Cheng
Journal: Annals of Oncology (2024)
578P Tertiary cancer prevention: A national evaluation of the practices and perceptions of hospital-based health care professionals (HHCPs) in charge of the follow-up (FU) care of cancer
Authors: T. Ben Ahmed, L. Veron, E. Dubois-Delaloge, T. Pudlarz, P. Abdayem, P. Vidican, A. Petureau, P. Schillinger, O. Caron, A. Bensen, S. Boucher, M. Khettab, P-E. Heudel, E. Bernard, C. Lefeuvre-Plesse, B. Fervers, I. Vaz Luis, S. Delaloge
Journal: Annals of Oncology (2024)
588P A retrospective analysis of cancer stage, comorbidity, performance status, and treatment modality in leading cancer sites among geriatric patients from a hospital-based cancer registry
Authors: K. Sivaranjini, A.S. Oak, S.A. Cheulkar, A. P, M. Lokhande, E. Dashmukhe, A. Thakadiyil, P. Gode, V. Mishra, S. Chavan, P. Chaturvedi, R. Dikshit
Journal: Annals of Oncology (2024)
688P The efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy for advanced KRAS-mutant non-small cell lung cancer
Authors: H. Qiang, Y. Zhang, Y. Wang, J. Li, L. Zhang, X. Ling, S. Cao, Y. Zhou, H. Du, R. Zhong, H. Zhong
Journal: Annals of Oncology (2024)
632P RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) + chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
Authors: Z. Ma, Y. Yu, X. Yu, X. Li, J. Cui, D. Wang, X. Wang, J. Wu, D. Huang, G. Li, N. Zhao, L. Liang, M. Song, S. Lu
Journal: Annals of Oncology (2024)
567P Content and effectiveness of decision aids for families with hereditary cancer: A scoping review
Authors: M.J. An, S-Y. Park, Y. Kim, Y-J. Kim, M.C. Katapodi, H. Chae, Y-J. Choi, K.H. Ryu, E-G. Lee, S-Y. Kong, S-Y. Jung
Journal: Annals of Oncology (2024)
633P Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
Authors: K. Yoh, F. Opdam, M. Barve, H. Tu, Y-L. Wu, D. Berz, L. Schroeter, B. Sadrolhefazi, J. Serra, J. Heymach, N. Yamamoto
Journal: Annals of Oncology (2024)
635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC
Authors: S. Lu, C. Zhou, B.C. Cho, A. Ono, H. Hayashi, M. Majem, S-H. Lee, G. Richardson, J.K. Sabari, N. Girard, R.E. Sanborn, A.S. Mansfield, N. Buyukkaramikli, N. Perualila, S. Acharya, C. Chandler, L. Dearden, T. Agrawal, M. Baig, K. Park
Journal: Annals of Oncology (2024)
570P NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
Authors: E. Le Rhun, L. Nayak, M.J. Lim Fat, R. Rudà, E. Pentsova, P. Forsyth, B. O'Brien, M. Preusser, P. Kumthekar, D. Brandsma, M. Weller
Journal: Annals of Oncology (2024)
625O Efficacy and safety of lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: A randomized, double-blind, placebo-controlled multicenter phase II trial
Authors: W.V. Fang, C. Wang, K. Wu, J. Fu, X. Lin, H. Zhang, J. Chen, Y. Zhang, P. Zhang, Y. Liu, Y. Zheng, P. Tang, Z. Gao, Q. Fan, X. Zhi, H. Cai, J. Zheng, M. Li, F. Li, C. Zhou
Journal: Annals of Oncology (2024)
Infant feces-derived <i>Lactobacillus gasseri</i> FWJL-4 mitigates experimental necrotizing enterocolitis <i>via</i> acetate production
Authors: Li-Long Pan, Yudong Sun, Xiaoliang Dong, Zhengnan Ren, Binbin Li, Ping Yang, Le Zhang, Jia Sun
Journal: Gut Microbes (2024)

Necrotizing enterocolitis (NEC) is a life-threatening disease in premature infants, characterized by high mortality. Recent studies increasingly highlight the role of gut dysbiosis in NEC pathogenesis. Although probiotics have shown some efficacy in preventing NEC, further research is needed to determine potential strains and approaches. In this study, we demonstrated that the novel probiotic strain Lactobacillus gasseri (L. gasseri) FWJL-4, isolated from the feces of healthy infants, significantly enhanced intestinal barrier function, providing substantial protection against NEC. This protective effect was attributed to elevated intestinal acetate levels. Notably, acetate supplementation alone was sufficient to mitigate NEC, mimicking the protective effects of L. gasseri FWJL-4. Mechanistically, we revealed that L. gasseri FWJL-4 inhibited necroptosis and preserved the number of the goblet cells and enterocytes through the production of the short-chain fatty acid acetate, via activation of the acetate receptors G protein-coupled receptor (GPR) 41 and GPR43. Our findings suggest that L. gasseri FWJL-4 enhances intestinal barrier function to protect against NEC, underscoring the potential of probiotic manipulation as a promising strategy for NEC prevention.
Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy
Authors: Gayathri R Ediriweera, Amal J Sivaram, Gary Cowin, Mikayla Brown, Luke McAlary, Jeremy S Lum, Nicholas L Fletcher, Liam Robinson, Joshua D Simpson, Liyu Chen, Joanna M Wasielewska, Ella Byrne, John W Finnie, Jim Manavis, Anthony R White, Justin J Yerbury, Kristofer J Thurecht, Kara L Vine
Journal: Journal of Controlled Release (2024)

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with extremely limited therapeutic options. One key pathological feature of ALS is the abnormal accumulation of misfolded proteins within motor neurons. Hence, reducing the burden of misfolded protein has emerged as a promising therapeutic approach. Antisense oligonucleotides (ASOs) have the potential to effectively silence proteins with gain-of-function mutations, such as superoxide dismutase 1 (SOD1). However, ASO delivery to the central nervous system (CNS) is hindered by poor blood-brain barrier (BBB) penetration and the invasiveness of intrathecal administration. In the current study, we demonstrate effective systemic delivery of a next-generation SOD1 ASO (Tofersen) into the brain of wildtype and G93A-SOD1 transgenic C57BL/6 mice using calcium phosphate lipid nanoparticles (CaP lipid NPs). We show that transcranial focused ultrasound (FUS) with intravenously administered microbubbles can significantly enhance ASO-loaded nanoparticle delivery into the mouse brain. Magnetic resonance imaging (MRI) and immunohistological analysis showed reduced SOD1 expression in the FUS-exposed brain regions and increased motor neuron count in the spinal cord of treated mice suggesting decreased motor neuron degeneration. Importantly, the BBB opening was transient without evidence of structural changes, neuroinflammation or damage to the brain tissue, indicating that the treatment is well tolerated. Overall, our results highlight FUS-assisted nanoparticle delivery of ASOs as a promising non-invasive therapeutic strategy for the treatment of ALS and CNS diseases more broadly.